» Articles » PMID: 35991621

Sympathetic Activation in Heart Failure

Overview
Date 2022 Aug 22
PMID 35991621
Authors
Affiliations
Soon will be listed here.
Abstract

Sympathetic activation has been long appreciated exclusively as a fundamental compensatory mechanism of the failing heart and, thus, welcome and to be supported. In the initial clinical phases of heart failure (HF), the sympathetic nervous system overdrive plays a compensatory function aimed at maintaining an adequate cardiac output despite the inotropic dysfunction affecting the myocardium. However, when the sympathetic reflex response is exaggerated it triggers a sequence of unfavourable remodelling processes causing a further contractile deterioration that unleashes major adverse cardiovascular consequences, favouring the HF progression and the occurrence of fatal events. Eventually, the sympathetic nervous system in HF was demonstrated to be a 'lethality factor' and thus became a prominent therapeutic target. The existence of an effective highly specialized intracardiac neuronal network immediately rules out the old concept that sympathetic activation in HF is merely the consequence of a drop in cardiac output. When a cardiac damage occurs, such as myocardial ischaemia or a primary myocardial disorder, the adaptive capability of the system may be overcame, leading to excessive sympatho-excitation coupled with attenuation till to abolishment of central parasympathetic drive. Myocardial infarction causes, within a very short time, both a functional and anatomical remodelling with a diffuse up-regulation of nerve growth factor (NGF). The subsequent nerve sprouting signal, facilitated by a rise in the levels of NGF in the left stellate ganglion and in the serum, triggers an increase in cardiac nerve density in both peri-infarct and non-infarcted areas. Finally, NFG production decreases over time, supposedly as an adaptative response to the prolonged exposure to sympathetic overactivity, leading in the end to a reduction in sympathetic nerve density. Accordingly, NGF levels were markedly reduced in patients with severe congestive heart failure. The kidney is the other key player of the sympathetic response to HF as it indeed reacts to under-perfusion and to loop diuretics to preserve filtration at the cost of many pathological consequences on its physiology. This vicious loop ultimately participates to the chronic and disruptive sympathetic overdrive. In conclusion, sympathetic activation is the natural physiological consequence to life stressors but also to any condition that may harm our body. It is the first system of reaction to any potential life-threatening event. However, in any aspect of life over reaction is never effective but, in many instances, is, actually, life threatening. One for all is the case of ischaemia-related ventricular fibrillation which is, strongly facilitated by sympathetic hyperactivity. The take home message? When, in a condition of harm, everybody is yelling failure is just around the corner.

Citing Articles

Early experience with baroreflex activation therapy from a vascular surgery perspective.

Chow C, Montoya C, Sussman M, Kenel-Pierre S, Velazquez O, Grazette L J Vasc Surg Cases Innov Tech. 2025; 10(6):101464.

PMID: 40027264 PMC: 11868725. DOI: 10.1016/j.jvscit.2024.101464.


Pharmacodynamics of single-dose omecamtiv mecarbil administered intravenously in clinically healthy cats.

Ishizaka M, Hsu H, Miyagawa Y, Takemura N Open Vet J. 2025; 14(12):3614-3624.

PMID: 39927371 PMC: 11799624. DOI: 10.5455/OVJ.2024.v14.i12.42.


Trajectory of Cardiogenic Dementia: A New Perspective.

AlRawili N, Al-Kuraishy H, Al-Gareeb A, Abdel-Fattah M, Al-Harchan N, Alruwaili M J Cell Mol Med. 2025; 29(2):e70345.

PMID: 39828641 PMC: 11742966. DOI: 10.1111/jcmm.70345.


Pathophysiology of Congestion in Heart Failure: A Contemporary Review.

Kumric M, Kurir T, Bozic J, Slujo A, Glavas D, Miric D Card Fail Rev. 2024; 10:e13.

PMID: 39450149 PMC: 11499970. DOI: 10.15420/cfr.2024.07.


Renal nerves in physiology, pathophysiology and interoception.

Evans L, Dayton A, Osborn J Nat Rev Nephrol. 2024; 21(1):57-69.

PMID: 39363020 DOI: 10.1038/s41581-024-00893-3.


References
1.
Ardell J, Armour J . Neurocardiology: Structure-Based Function. Compr Physiol. 2016; 6(4):1635-1653. DOI: 10.1002/cphy.c150046. View

2.
Dibner-Dunlap M, Thames M . Control of sympathetic nerve activity by vagal mechanoreflexes is blunted in heart failure. Circulation. 1992; 86(6):1929-34. DOI: 10.1161/01.cir.86.6.1929. View

3.
Jacobson A, Senior R, Cerqueira M, Wong N, Thomas G, Lopez V . Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010; 55(20):2212-21. DOI: 10.1016/j.jacc.2010.01.014. View

4.
Paintal A . Vagal sensory receptors and their reflex effects. Physiol Rev. 1973; 53(1):159-227. DOI: 10.1152/physrev.1973.53.1.159. View

5.
Ardell J, Butler C, Smith F, Hopkins D, Armour J . Activity of in vivo atrial and ventricular neurons in chronically decentralized canine hearts. Am J Physiol. 1991; 260(3 Pt 2):H713-21. DOI: 10.1152/ajpheart.1991.260.3.H713. View